95 related articles for article (PubMed ID: 26768954)
1. Surgery and hormone therapy trends in octogenarians with invasive breast cancer.
Kantor O; Pesce C; Liederbach E; Wang CH; Winchester DJ; Yao K
Am J Surg; 2016 Mar; 211(3):541-5. PubMed ID: 26768954
[TBL] [Abstract][Full Text] [Related]
2. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
3. The role of primary endocrine therapy in older women with operable breast cancer.
Johnston SJ; Cheung KL
Future Oncol; 2015; 11(10):1555-65. PubMed ID: 25963432
[TBL] [Abstract][Full Text] [Related]
4. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
5. Lack of knowledge of hormone receptor status and use of endocrine therapy in invasive breast cancer.
Bell RJ; Lijovic M; Fradkin P; Bradbury J; La China M; Schwarz M; Wolfe R; Farrugia H; Davis SR
J Womens Health (Larchmt); 2009 Dec; 18(12):1975-80. PubMed ID: 20044859
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery.
Murphy CT; Li T; Wang LS; Obeid EI; Bleicher RJ; Eastwick G; Johnson ME; Hayes SB; Weiss SE; Anderson PR
Clin Breast Cancer; 2015 Oct; 15(5):381-9. PubMed ID: 25861716
[TBL] [Abstract][Full Text] [Related]
7. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
8. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients.
Kennedy T; Stewart AK; Bilimoria KY; Patel-Parekh L; Sener SF; Winchester DP
Ann Surg Oncol; 2007 Oct; 14(10):2918-27. PubMed ID: 17638060
[TBL] [Abstract][Full Text] [Related]
9. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Salmon RJ; Alran S; Malka I; de Cremoux P; Rosty C; Languille O; Campana F; ; Sigal-Zafrani B
Am J Clin Oncol; 2006 Aug; 29(4):385-8. PubMed ID: 16891867
[TBL] [Abstract][Full Text] [Related]
12. Surgery improves breast cancer-specific survival in octogenarians with early-stage breast cancer.
Cortadellas T; Gascón A; Córdoba O; Rabasa J; Rodríguez R; Espinosa-Bravo M; Esgueva A; Rubio IT; Xercavins J; Gil A
Int J Surg; 2013; 11(7):554-7. PubMed ID: 23721662
[TBL] [Abstract][Full Text] [Related]
13. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
14. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.
Kok M; Koornstra RH; Mook S; Hauptmann M; Fles R; Jansen MP; Berns EM; Linn SC; Van 't Veer LJ
Breast; 2012 Dec; 21(6):769-78. PubMed ID: 22738860
[TBL] [Abstract][Full Text] [Related]
15. A predictive model for the development of hormone-responsive breast cancer.
Gorla SR; Hou N; Acharya S; Rademaker A; Khan S; Staradub V; Morrow M
Ann Surg Oncol; 2005 Jan; 12(1):48-56. PubMed ID: 15827778
[TBL] [Abstract][Full Text] [Related]
16. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
Christiansen P; Bjerre K; Ejlertsen B; Jensen MB; Rasmussen BB; Lænkholm AV; Kroman N; Ewertz M; Offersen B; Toftdahl DB; Møller S; Mouridsen HT;
J Natl Cancer Inst; 2011 Sep; 103(18):1363-72. PubMed ID: 21881042
[TBL] [Abstract][Full Text] [Related]
17. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study.
Martelli G; Miceli R; Costa A; Coradini D; Zurrida S; Piromalli D; Vetrella G; Greco M
Cancer; 2008 Feb; 112(3):481-8. PubMed ID: 18098268
[TBL] [Abstract][Full Text] [Related]
18. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
19. Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: a review of the literature.
Boswell KA; Wang X; Shah MV; Aapro MS
Breast; 2012 Dec; 21(6):701-6. PubMed ID: 23092824
[TBL] [Abstract][Full Text] [Related]
20. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]